Recombinant Human Serpin B9 (C-6His)

Recombinant Human Serpin B9 (C-6His)

Size1:10μg price1:$98
Size2:50μg price2:$248
Size3:500μg price3:$1680
SKU: PHH1508 Category: Target Proteins Tags: ,

Datasheet

Name

Recombinant Human Serpin B9 (C-6His)

Purity

Greater than 95% as determined by reducing SDS-PAGE

Endotoxin level

<1 EU/µg as determined by LAL test.

Construction

Recombinant Human Serine Protease Inhibitor-clade B9 is produced by our Mammalian expression system and the target gene encoding Met1-Pro376 is expressed with a 6His tag at the C-terminus.

Accession #

P50453

Host

Human Cells

Species

Human

Predicted Molecular Mass

43.4 KDa

Buffer

Lyophilized from a 0.2 μm filtered solution of 20mM PB, 150mM NaCl, pH 7.4.

Form

Lyophilized

Shipping

The product is shipped at ambient temperature.Upon receipt, store it immediately at the temperature listed below.

Stability&Storage

Store at ≤-70°C, stable for 6 months after receipt.Store at ≤-70°C, stable for 3 months under sterile conditions after opening. Please minimize freeze-thaw cycles.

Reconstitution

Always centrifuge tubes before opening.Do not mix by vortex or pipetting.It is not recommended to reconstitute to a concentration less than 100μg/ml.Dissolve the lyophilized protein in distilled water.Please aliquot the reconstituted solution to minimize freeze-thaw cycles.

 

 

 

Alternative Names

Cytoplasmic antiproteinase 3;Peptidase inhibitor 9;CAP3;PI-9;Serpin B9

 

Background

Serpin B9, also known as Cytoplasmic antiproteinase 3(CAP-3), is a cytoplasm protein which belongs to the large superfamily of serine proteinase inhibitors (serpins), which bind to and inactivate serine proteinases. Serpin B9 is an inhibitor of the granzyme B/perforin lytic pathway. It is expressed in normal mammary epithelial cells but not in most mammary carcinoma cell lines. These interactions are involved in many cellular processes, including coagulation, fibrinolysis, complement fixation, matrix remodeling, and apoptosis. Serpin-B9 expression in immune-privileged cells, APCs, and CTLs protects these cells against the actions of granzyme B, and when expressed in tumor cells or virally infected hepatocytes, confers resistance to killing by CTL and NK cells. Expression of increasing levels of Serpin-B9 in target cells may progressively inhibit immune surveillance by blocking NK and CTL-induced cytotoxicity through the perforin / granzyme pathway and then through the Fas / FasL pathway.

 

Note

For Research Use Only , Not for Diagnostic Use.